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The cornerstone of the treatment of metastatic non-smallcell lung cancer (NSCLC) is cytotoxic chemotherapy,
given either as a platinum-based doublet for chemotherapy-
naive patients or as a single agent for patients with previously
treated disease. Despite extensive testing of different combi-
nation regimens over the past two decades, the overall im-
provements in terms of patient survival have been modest.1
To illustrate this point, four standard platinum-based regi-
mens were compared in a randomized trial of 1155 patients
with untreated advanced inoperable NSCLC.2 There were no
statistically significant differences in response rates or 1-year,
2-year, or overall survival between the different regimens.
Similarly, no differences in response rates, median survival,
or 1-year survival were seen in a large randomized trial
comparing docetaxel and pemetrexed in patients with previ-
ously treated NSCLC.3It appears that a plateau in efficacy has
been achieved with cytotoxic chemotherapy, and new thera-
peutic approaches are needed.
Improvements in our understanding of cancer biology
have led to the development of new classes of therapeutic
agents that more specifically target either the tumor cell or its
supporting milieu. Inhibition of angiogenesis, which is the
development of new blood vessels, is one treatment strategy
that has shown promise.4 To grow beyond a few millimeters
in diameter, solid tumors must develop a vascular supply.
Chief among the mediators of angiogenesis is vascular endo-
thelial growth factor (VEGF). VEGF regulates several differ-
ent functions including vascular permeability, endothelial
migration and proliferation, and the promotion of tumor
angiogenesis.5 Therefore, blockade of the VEGF axis would
be expected to slow tumor growth and decrease the potential
for metastatic spread. VEGF blockade has also been shown to
improve the efficacy of cytotoxic chemotherapy, potentially
through increasing endothelial apoptosis and/or transiently
improving tumor blood flow through vessel normalization.6,7
There are a number of strategies through which the
effects of VEGF can be inhibited. Targeting the ligand with
monoclonal antibodies such as bevacizumab has proven suc-
cessful in a broad range of tumors.8,9 The approach of
blocking the VEGF receptor (VEGFR) tyrosine kinase
through small-molecule tyrosine kinase inhibitors has also
demonstrated promise for several tumor types.10,11
MATERIALS AND METHODS
Bevacizumab in NSCLC
In phase I clinical trials, bevacizumab was well toler-
ated both as a monotherapy and when given in combination
with cytotoxic chemotherapy.12,13 It was the first antiangio-
genic agent to be approved for use based on a pivotal study
demonstrating improved survival for patients with colorectal
cancer who received combination of bevacizumab with iri-
notecan, 5-fluorouracil, and leucovorin.8
The use of bevacizumab in advanced NSCLC was first
explored in a randomized phase II trial study comparing the
standard chemotherapy doublet of paclitaxel (200 mg/m2)
plus carboplatin (area under the curve [AUC]  6) alone or
with bevacizumab given at either low (7.5 mg/kg) or high (15
mg/kg) doses. The response rate (40% for high-dose bevaci-
zumab versus 21.9% for low-dose bevacizumab versus 31.3%
for standard therapy), time to tumor progression (TTP) (7
months versus 4.1 months versus 5.9 months), and median
survival (17.7 months versus 11.6 months versus 14.9
months) all favored the high-dose bevacizumab arm over the
low-dose and standard arms, respectively.14
This study also highlighted potential toxicities of
VEGF blockade therapy in NSCLC. These included hyper-
tension, thrombotic events, hemorrhagic events, and protein-
uria. Six patients experienced significant hemoptysis or he-
matemesis, with four of the cases occurring in patients with
squamous cell carcinoma. Four of the hemorrhagic events
were fatal. The risk of hemorrhage did not appear to be dose
related, as five of the six events occurred in the low-dose
bevacizumab arm. As these events were primarily seen in
patients with squamous cell histology, these patients were
excluded from subsequent trials, including the recently re-
ported randomized phase III study in NSCLC.
Based on the results of the randomized phase II study in
chemotherapy-naive patients with NSCLC, the Eastern Co-
operative Oncology Group (ECOG) designed a phase III trial
exploring he efficacy of the addition of bevacizumab to a
standard chemotherapy doublet, paclitaxel/carboplatin (PC)
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(ECOG 4599). In this trial, 878 patients with chemotherapy-
naive metastatic nonsquamous NSCLC were randomized to
receive either PC or the same regimen with the addition of 15
mg/kg of bevacizumab (PCB). This study demonstrated the
superiority of PCB to PC, with statistically significant im-
provements in median survival (12.5 months for PCB versus
10.2 months for PC) (Table 1), response rate (27% versus
10%), and progression-free survival (PFS) (6.4 months versus
4.5 months).9 The results of ECOG 4599 have validated
VEGF and tumor angiogenesis as therapeutic targets in the
treatment of metastatic NSCLC.
Sorafenib In NSCLC
BAYER 43-9006 (sorafenib) is a potent oral, multitar-
geted, signal transduction inhibitor. Specifically, sorafenib
inhibits raf-kinases, VEGF receptor (VEGFR)-2, platelet-
derived growth factor receptor (PDGFR)-, and c-kit.15 Sor-
afenib has been evaluated as a single agent at a dose of 400
mg orally twice daily in multiple tumor types and has been
recently approved based on the results of a randomized phase
III trial in renal cell cancer (RCC).
In this randomized trial, 884 patients with advanced
RCC were randomized to either 400 mg twice daily of
sorafenib or placebo. The patients treated on the sorafenib
arm achieved a PFS of 24 weeks versus 12 weeks for those
randomized to placebo (p  0.00001).11 Principal toxicities
included skin rash (34%), diarrhea (33%), fatigue (26%), and
hypertension (11%). Hand and foot skin reaction was seen in
27% of patients treated with sorafenib.
A phase II single-arm study of sorafenib in patients
with refractory or recurrent NSCLC was recently completed.
Eligible patients had metastatic NSCLC including squamous
cell carcinoma and an ECOG performance status of 0 to 2,
and were allowed one to two prior therapies for their disease.
Fifty-two patients were enrolled on study, with 48 assessable
for the primary endpoint, response rate. Although no partial
responses were reported, 30 patients had stable disease, with
23 patients demonstrating some degree of tumor shrinkage.
The TTP reported was 103 days. Adverse events (grade 3 or
4) included hand and foot syndrome and fatigue. There were
two patients with grade 3 hemoptysis. One of the patients
subsequently developed a grade 5 hemoptysis after discon-
tinuation of drug.16
Sorafenib at 400 mg twice daily has also been com-
bined successfully with chemotherapy without evidence of
pharmacokinetic interaction when given on days 2 through 19
of a 21-day chemotherapy cycle.17 The combination of pac-
litaxel and carboplatin with sorafenib resulted in partial
responses in 11 of 35 patients with melanoma and in five of
14 patients with metastatic NSCLC.18
Based on the preliminary activity and acceptable safety
profile of this combination, a randomized phase III study
comparing paclitaxel (200 mg/m2) plus carboplatin (AUC 
6) versus the same regimen with the addition of sorafenib at
400 mg twice daily in chemotherapy-naive patients with
advanced NSCLC is currently accruing patients (Figure 1).
Additional studies are planned, including a phase I dose-
escalation study combining sorafenib with the PCB combi-
nation in patients with untreated advanced NSCLC.
BIBF 1120 in Solid Tumors.
BIBF 1120 is an oral, mutitargeted, tyrosine kinase
inhibitor that is a potent inhibitor of VEGFR-2 and also has
activity against VEGFR-1 and -3, PDGFR-, and fibroblastic
growth factor receptor-1 and -3. Dr. Schiller presented data
regarding phase I monotherapy studies and the ongoing phase
I study of BIBF 1120 with carboplatin and paclitaxel.19,20 As
once-daily monotherapy, the most frequent toxicities have
been nausea, vomiting, diarrhea, abdominal pain, and fatigue,
all of which were grade 2 or less. The maximum tolerated
dose is 400 mg per day. Dose-limiting toxicity was grade 3
reversible asymptomatic elevations in liver enzymes. Twice-
daily dosing was also investigated to increase drug exposure
on a schedule of 28 days’ continuous dosing followed by a
7-day break. Similar toxicities to the once-daily dosing
schedule were seen, including grade 2 nausea, vomiting, and
diarrhea, with elevations in the liver enzymes being the
TABLE 1. Results of randomized phase II/III trial (ECOG





(n  434) p-value
Efficacy
ORR (%) 10 27.1 0.0001
PFS (m) 4.5 6.4 0.001
OS (m) 10.2 12.5 0.007
Toxicity (grade 3)
Hemorrhage (%) 0.7 4.5 0.001
Hypertension (%) 0.7 6.0 0.001
PC, paclitaxel and carboplatin; PCB, paclitaxel, carboplatin, and bevacizumab;
ORR, overall response rate; PFS, progression-free survival; OS, overall survival.
FIGURE 1. Schema depicting design of ongoing random-
ized phase III trial comparing paclitaxel/carboplatin with or
without sorafenib. Reprinted with permission from Ronit
Simantov, M.D.
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dose-limiting toxicity. Based on increased drug exposure
over single daily dosing with comparable toxicity profiles, the
recommended dose of BIBF 1120 is 250 mg orally twice
daily. Currently under evaluation in a combination phase I
trial, BIBF 1120 is being dose escalated on a twice-daily
schedule while being given with carboplatin (AUC  6) and
paclitaxel (200 mg/m2) in patients with chemotherapy-naive
advanced NSCLC.
ZD6474 for NSCLC
Recent results of two randomized, phase II clinical
trials using ZD6474 (Zactima; AstraZeneca, Macclesfield,
U.K.) for NSCLC were reported by Dr. Ron Natale. ZD6474
is an oral inhibitor with specificity for the VEGFR-2, epider-
mal growth factor receptor (EGFR), and RET receptor ty-
rosine kinases. ZD6474 has the potential to offer both direct
antitumor effects by inhibiting EGFR and antiangiogenic
effects by targeting VEGFR-2 and EGFR on tumor endothe-
lium.
Two phase I dose-escalation studies have demonstrated
that the drug was generally well tolerated in daily oral doses
up to 300 mg/day.21,22 The most common adverse events
were rash, diarrhea, and asymptomatic QTc interval prolon-
gation. These side effects were generally mild and manage-
able using standard treatments such as antidiarrheal agents or
by dose reduction. The pharmacokinetic profile was compat-
ible with once-daily oral dosing, with a terminal half-life of
greater than 120 hours in both phase I studies. In the phase I
study conducted in Japan, partial responses were observed in
four of nine patients with NSCLC, suggesting that the drug
has single-agent activity in NSCLC.
Based on these results, two randomized, double-blind,
placebo-controlled, phase II studies were conducted. In the
first, previously treated NSCLC patients were treated with
either ZD6474 (300 mg by mouth [PO] once daily) or
gefitinib (250 mg PO once daily).23 The primary endpoint
was PFS, and patients with disease progression were permit-
ted to crossover to the other arm after a 4-week washout
period. There were 83 and 85 patients in the ZD6474 and
gefitinib arms, respectively, and the groups were well bal-
anced with respect to major prognostic factors. The study
achieved its primary endpoint, with a 58% prolongation of
PFS observed in the ZD6474 arm (11.9 versus 8.1 weeks; p
0.011), corresponding to a hazard ratio for progression of
0.632 (Figure 2). Furthermore, after crossover, a higher
disease control rate was observed in patients receiving
ZD6474 than in those receiving gefitinib.
A second randomized phase II study evaluated ZD6474
in combination with chemotherapy in previously treated
NSCLC patients. In this trial, patients received the drug, at
doses of either 100 mg or 300 mg PO once daily, in combi-
nation with docetaxel as compared with a control arm con-
sisting of docetaxel with placebo.24 An improvement in PFS
was observed in the ZD6474 100-mg arm, with a 57%
prolongation in PFS (18.7 weeks versus 12.0 weeks in the
docetaxel control arm; p  0.07), corresponding to a hazard
ratio of 0.64. A lesser improvement was observed in the
300-mg arm, with a hazard ratio of 0.83.
These data support further clinical investigation of this
agent, both as a single agent and in combination with che-
motherapy. Ongoing trials include a randomized phase II
study of ZD6474 versus carboplatin/paclitaxel versus the
combination of the three drugs.25 There is also a National
Cancer Institute of Canada study evaluating ZD6474 in pa-
tients with small cell lung cancer who had an initial response
to first-line chemotherapy. Finally, a randomized phase III
trial comparing docetaxel with or without ZD6474 (100 mg
PO once daily) has recently started accrual. Clinical trials
evaluating ZD6474 monotherapy in second- and third-line
NSCLC are currently being considered as well.
Targeting Tumor and Tumor Endothelial Cells
Using AEE788.
Preclinical studies presented by Dr. Amir Onn explored
the antitumor effects of AEE788. This agent is a dual
VEGF2/EGFR inhibitor but, unlike ZD6474, is a more potent
inhibitor of EGFR than VEGFR-2. In two murine orthotopic
NSCLC models (H441 and PC14-PE6), AEE788 inhibited
the growth of primary lung tumors. In addition, there was also
a significant reduction in the incidence of metastases and
pleural effusions. Furthermore, the combination of AEE788
and paclitaxel was more effective in both models than either
of the drugs individually.
The mechanism of this antitumor activity was investi-
gated in greater detail. In the H441 model, which was found
to be more responsive to AEE788, higher expression levels of
EGFR ligands (transforming growth factor- and EGF) was
present, providing a possible explanation for the higher levels
of phosphorylated EGFR observed. These tumor cells also
induced the expression of EGFR on endothelial cells, both in
vitro and in xenografts. Treatment with AEE788 inhibited
EGFR phosphorylation in tumor cells and tumor-associated
endothelium. This suggests that the efficacy of AEE788 in
this model may be attributable, at least in part, to inhibition of
EGFR expressed in tumor-associated endothelium and tumor
cells.
FIGURE 2. Progression-free survival (PFS) analysis from a
randomized phase II study of NSCLC patients treated with
either ZD6474 (n  83) or gefitinib (n  85).23 Reprinted
with permission from Ronald B. Natale, M.D.
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Sunitinib and AZD2171 for NSCLC and Other
Solid Tumors
Sunitinib (SU11248, Sutent; Pfizer, New York, NY) is
an oral, multitargeted inhibitor of multiple receptor tyrosine
kinases (RTKs) including VEGFR-1, -2, and -3; PDGFR;
KIT; and FLT-3.26 Compared with other RTK inhibitors in
clinical use, sunitinib has a relatively broad spectrum of
activity against a range of potential therapeutic targets.27The
drug received U.S. Food and Drug Administration approval
in January of 2006 for both advanced RCC and imatinib-
refractory gastrointestinal stromal tumor. The approval for
RCC was based on two single-arm studies, in which overall
response rates of 26 to 37% were observed.10 The gastroin-
testinal stromal tumor approval was based on a randomized
study in which TTP was prolonged for patients treated with
sunitinib compared with the placebo control arm (27 weeks
versus 6 weeks).28 Despite this substantial improvement in
TTP, however, the overall tumor response rate judged by
Response Evaluation Criteria in Solid Tumors criteria was a
modest 6.8%, illustrating that conventional methods for as-
sessing response may not accurately depict the clinical benefit
provided by a targeted agent.
Adverse events associated with sunitinib treatment in-
clude fatigue, nausea, diarrhea, left ventricular dysfunction,
hypertension, and tumor-associated hemorrhage. Two pa-
tients with metastatic NSCLC experienced fatal pulmonary
hemorrhage. Both patients had squamous histology, suggest-
ing that the increased risk for fatal pulmonary hemorrhage
initially observed in a phase II trial of bevacizumab with
chemotherapy14 is likely to apply to other antiangiogenic
agents as well.
Sunitinib is currently undergoing clinical evaluation for
advanced or metastatic NSCLC in a variety of different
treatment regimens. In one trial, sunitinib is being tested as
monotherapy in patients whose disease has progressed after
platinum-based chemotherapy. It is also being tested as main-
tenance therapy after carboplatin and paclitaxel, in combina-
tion with platinum-based doublets, and in combination with
erlotinib.
AZD2171 is an oral, multitargeted kinase inhibitor with
activity against VEGFR-1, -2, and -3 and c-kit.29 It is a
particularly potent inhibitor of VEGFR-2, with a 50% inhib-
itory concentration of less than 1 nM. In phase I testing,
AZD2171 was tested at doses up to 60 mg once daily. There
was an apparent greater degree of stable disease at higher
doses, and a greater degree of biomarker modulation and an
increased frequency of toxicities such as hypertension and
fatigue.30 Preliminary results from clinical trials of AZD2171
for NSCLC were presented by Dr. Frances Shepherd. A phase
I study was conducted with AZD2171, at doses of 30 mg and
45 mg daily, in combination with carboplatin and paclitaxel
for previously untreated patients. Common adverse events
included fatigue, diarrhea, and hypertension, which was man-
aged with the use of a standard treatment algorithm. Clear
evidence of clinical activity was observed. Consistent with
earlier studies of bevacizumab, cavitary lesions were also
observed.
Based on the results of this phase I study, a randomized
phase II/III trial has been initiated. This trial will permit
patients with all NSCLC histologies, including squamous cell
carcinoma, and patients with brain metastases provided that
they are clinically stable without the use of steroids. The
primary endpoint for the phase II trial is PFS, and an interim
safety and efficacy analysis will be conducted at the end of
the phase II trial to determine whether the trial proceeds to the
phase III component.
CONCLUSIONS
The recent success of bevacizumab in combination with
chemotherapy for NSCLC and other solid tumors8,9 has
validated tumor angiogenesis as a therapeutic target and
stimulated the clinical development of numerous antiangio-
genic agents for NSCLC. The majority of these are small-
molecule receptor tyrosine kinase inhibitors of the VEGFR
family, although many also target structurally related RTKs
such as PDGFR and c-kit. Among these newer agents,
ZD6474, a dual VEGFR/EGFR inhibitor, is the most ad-
vanced in clinical development in lung cancer. In two ran-
domized phase II trials, prolonged PFS was observed in
patients treated with ZD6474, either as a single agent com-
pared with gefitinib,23 or in combination with docetaxel as
compared with docetaxel alone.24 Phase III trials evaluating
this agent are ongoing. Other promising agents include the
multitargeted RTK inhibitors AZD2171, sunitinib, and sor-
afenib. These agents are all undergoing further clinical eval-
uation in advanced NSCLC, generally in combination with
either chemotherapy or EGFR inhibitors. In addition to the
known class effects such as hypertension, these agents appear
to increase the risk of pulmonary hemorrhage when used in
NSCLC patients, a potentially fatal and poorly understood
phenomenon. Critical areas for future investigation include
the identification of targets other than VEGF involved in
NSCLC tumor angiogenesis; an improved understanding of
how VEGF inhibitors should be integrated with other treat-
ment modalities and targeted agents; and the development of
biomarkers for identifying patients likely to benefit from
treatment or experience serious toxicities.
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